Amadeus, Nycomed, Phadia trigger up to Eu7bn prepayments for leverage lenders
Leveraged loan investors could be facing up to Eu7bn of prepayments following the sales of drug company Nycomed and blood testing group Phadia, and a refinancing for travel technology firm Amadeus that was clubbed between bank lenders.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
